Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.53 |
| ▸ | NCF1 | P14598 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | HTR5A | P47898 | 2/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28194684 | 0.87 | KDM4E (0.71) | HTR6NCF1HTR1AHTR2AHTR7 | |
| SCHEMBL28241794 | 0.84 | ALDH1A1 (0.57) | NCF1KDM4EALDH1A1HPGD | |
| SCHEMBL11321507 | 0.82 | ALDH1A1 (0.57) | NCF1TSHRKDM4EALDH1A1HPGD | |
| SCHEMBL24524524 | 0.81 | KDM4E (0.77) | NCF1CYP1A2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL3588307 | 0.79 | ALDH1A1 (0.53) | NCF1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30725496 | 0.78 | HTR2C (0.56) | HTR6NCF1HTR1AHTR2AHTR7 | |
| SCHEMBL9303783 | 0.78 | HTR2C (0.56) | HTR6NCF1HTR1AHTR2AHTR7 | |
| SCHEMBL8812194 | 0.78 | KDR (0.48) | HTR6HTR1AHTR2AHTR7HTR1D | |
| SCHEMBL3556088 | 0.78 | KDR (0.51) | HTR6HTR1AHTR2AHTR7HTR1D | |
| SCHEMBL3556090 | 0.77 | ALDH1A1 (0.42) | HTR6NCF1HTR1AHTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118742543-A | Dihydro isoquinoline compound and medical application thereof | 中国科学院上海药物研究所 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023174383-A1 | DIHYDROISOQUINOLINE COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2023-09-21 | — | — | WO | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-7153849-B2 | Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans | WYETH (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060276481-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| EP-1537121-A1 | ANTIDEPRESSANT ARYLPIPERAZINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040142926-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-22 | — | — | US | disclosed |
| WO-2004024731-A1 | ANTIDEPRESSANT ARYLPIPERAZINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276481-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | HTR5A, CRH, TAAR5 | HTR6 62/4885NCF1 2251/4885HTR1A 51/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | HTR6 101/4885NCF1 3807/4885HTR1A 52/4885 |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | HTR5A, HTR2C, HTR1D | HTR6 16/4885NCF1 3837/4885HTR1A 4/4885 |
| US-20040142926-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | HTR5A, CYP19A1, CRH | HTR6 65/4885NCF1 2098/4885HTR1A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.